Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Baylor University Medical Center
mi
from
Irving, TX
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Baylor University Medical Center
mi
from
Irving, TX
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
North Texas Gastroenterology
mi
from
Lewisville, TX
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
North Texas Gastroenterology
mi
from
Lewisville, TX
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Gastroenterology Clinic of San Antonio
mi
from
San Antonio, TX
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Gastroenterology Clinic of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Advanced Research Institute
mi
from
Ogden, UT
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Advanced Research Institute
mi
from
Ogden, UT
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
McGuire VAMC
mi
from
Richmond, VA
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
McGuire VAMC
mi
from
Richmond, VA
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Seattle Gastroenterology Associates
mi
from
Seattle, WA
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Seattle Gastroenterology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Tacoma Digestive Disease Research
mi
from
Tacoma, WA
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Tacoma Digestive Disease Research
mi
from
Tacoma, WA
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Discovery Research International
mi
from
Milwaukee, WI
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Discovery Research International
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated:  2/6/2018
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis
Status: Enrolling
Updated: 2/6/2018
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Status: Enrolling
Updated:  2/7/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Status: Enrolling
Updated: 2/7/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated:  2/7/2018
Stanford
mi
from
Palo Alto, CA
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated: 2/7/2018
Stanford
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated:  2/7/2018
Stanford University Medical Center
mi
from
Palo Alto, CA
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated: 2/7/2018
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated:  2/7/2018
Stanford University Medical Center
mi
from
Palo Alto, CA
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease
Status: Enrolling
Updated: 2/7/2018
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Use of Fenofibrate for Primary Biliary Cirrhosis
Pilot Study of Fenofibrate for Primary Biliary Cirrhosis
Status: Enrolling
Updated:  2/7/2018
University of Florida
mi
from
Gainesville, FL
Use of Fenofibrate for Primary Biliary Cirrhosis
Pilot Study of Fenofibrate for Primary Biliary Cirrhosis
Status: Enrolling
Updated: 2/7/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Use of Fenofibrate for Primary Biliary Cirrhosis
Pilot Study of Fenofibrate for Primary Biliary Cirrhosis
Status: Enrolling
Updated:  2/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Use of Fenofibrate for Primary Biliary Cirrhosis
Pilot Study of Fenofibrate for Primary Biliary Cirrhosis
Status: Enrolling
Updated: 2/7/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Vitamin D Deficiency in Patients With Hypertension
Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension
Status: Enrolling
Updated:  2/9/2018
University of Connecticut Health Center
mi
from
Farmington, CT
Vitamin D Deficiency in Patients With Hypertension
Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension
Status: Enrolling
Updated: 2/9/2018
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Enrolling
Updated:  2/11/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status: Enrolling
Updated: 2/11/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients
Status: Enrolling
Updated:  2/12/2018
California Cancer Associates for Research and Excellence
mi
from
Encinitas, CA
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients
Status: Enrolling
Updated: 2/12/2018
California Cancer Associates for Research and Excellence
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients
Status: Enrolling
Updated:  2/12/2018
Peninsula and South Eastern Haematology and Oncology Grou
mi
from
Frankston,
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients
Status: Enrolling
Updated: 2/12/2018
Peninsula and South Eastern Haematology and Oncology Grou
mi
from
Frankston,
Click here to add this to my saved trials
Celiac Plexus Block for Chronic Pancreatitis RCT
Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis
Status: Enrolling
Updated:  2/12/2018
Los Angeles County Hospital
mi
from
Los Angeles, CA
Celiac Plexus Block for Chronic Pancreatitis RCT
Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis
Status: Enrolling
Updated: 2/12/2018
Los Angeles County Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessment of the Potential for Pressure Ulcer Formation
Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Status: Enrolling
Updated:  2/12/2018
UCIMC
mi
from
Orange, CA
Assessment of the Potential for Pressure Ulcer Formation
Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging
Status: Enrolling
Updated: 2/12/2018
UCIMC
mi
from
Orange, CA
Click here to add this to my saved trials
Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients
Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography
Status: Enrolling
Updated:  2/12/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients
Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography
Status: Enrolling
Updated: 2/12/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Validation Study of Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Status: Enrolling
Updated:  2/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Validation Study of Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
Status: Enrolling
Updated: 2/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
Status: Enrolling
Updated:  2/13/2018
Johns Hopkins Bayview Center for Learning and Health
mi
from
Baltimore, MD
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
Status: Enrolling
Updated: 2/13/2018
Johns Hopkins Bayview Center for Learning and Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of California San Diego Medical Center
mi
from
San Diego, CA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of Colorado Denver
mi
from
Aurora, CO
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of Florida
mi
from
Gainesville, FL
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of Miami
mi
from
Miami, FL
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
IMIC
mi
from
Palmetto Bay, FL
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
IMIC
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Tampa General Medical Group
mi
from
Tampa, FL
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Tampa General Medical Group
mi
from
Tampa, FL
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Piedmont Hospital
mi
from
Atlanta, GA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Feinberg School of Medicine, Northwestern University
mi
from
Chicago, IL
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Feinberg School of Medicine, Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Indiana University School of Medicine
mi
from
Indianapolis, IN
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Mercy Medical Center
mi
from
Baltimore, MD
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Mercy Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of Michigan
mi
from
Ann Arbor, MI
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Henry Ford Health System
mi
from
Detroit, MI
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
North Shore University Hospital
mi
from
Manhasset, NY
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Columbia University Medical Center
mi
from
New York, NY
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated:  2/13/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Status: Enrolling
Updated: 2/13/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials